The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin
Open accessAbstract
Ferroportin (FPN) mediates iron export from cells; FPN mutations are associated with the iron overloading disorder hemochromatosis. Previously, we found that the A77D, V162del, and G490D mutations inhibited FPN activity, but that other disease-associated FPN variants retained full iron export capability. The peptide hormone hepcidin inhibits FPN as part of a homeostatic negative feedback loop. We measured surface expression and function of wild-type FPN and fully active FPN mutants in the presence of hepcidin. We found that the Y64N and C326Y mutants of FPN are completely resistant to hepcidin inhibition and that N144D and N144H are partially resistant. Hemochromatosis-associated FPN mutations, therefore, either reduce iron export ability or produce an FPN variant that is insensitive to hepcidin. The former mutation type is associated with Kupffer-cell iron deposition and normal transferrin saturation in vivo, whereas patients with the latter category of FPN mutation have high transferrin saturation and tend to deposit iron throughout the liver parenchyma. FPN-linked hemochromatosis may have a variable pathogenesis depending on the causative FPN mutant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Deficits in hepcidin-mediated regulation of FPN, often due to hereditary hemochromatoses, lead to iron overload and widespread tissue damage affecting the liver, heart, pancreas, and joints 11-13 .”
From Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms (2020) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several hereditary hemochromatosis mutations in FPN directly coordinate Co 2+ in the C domain, including C326S/F/Y 13,29-31 and H507R 32 .”
From Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms (2020) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several FPN mutations decrease hepcidin binding to FPN, including N144H/D/T 34-36 , C326S/F/Y 13,29-31 , Y333H 37 , Y501C 7,38 , D504N 7,39 and H507R 32 .”
From Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms (2020) · cites this paper as [13]
Experimental — accuracy not yet measuredIn the citing paper
“It is essential to the development of these cell types as Spic −/− mice have drastically reduced numbers of RPM and EIM which lead to reduced proerythroblast numbers in the steady state, supporting the idea that iron recycling is essential to sustain iron-sufficient erythropoiesis [58].”
From “Pumping iron”—how macrophages handle iron at the systemic, microenvironmental, and cellular levels (2017) · cites this paper as [58]
In the citing paper
“Missense mutations that affected the subcellular localization or transporter function of ferroportin (”
From Forging a field: the golden age of iron biology. (2008) · cites this paper as [159]
In the citing paper
“In contrast, missense mutations that rendered ferroportin insensitive to regulation by hepcidin (”
From Forging a field: the golden age of iron biology. (2008) · cites this paper as [159]
In the citing paper
“These issues were resolved by the discovery that there are 2 broad categories of ferroportin mutations.158,159”
From Forging a field: the golden age of iron biology. (2008) · cites this paper as [159]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
Feder, J. N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D. A., Basava, A., Dormishian, F., Domingo, R., Ellis, M. C., Fullan, A., et al. (1996) · Nature Genetics · doi:10.1038/ng0896-399 · Cited by 3,664
Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter
Donovan, A., Brownlie, A., Zhou, Y., Shepard, J., Pratt, S. J., Moynihan, J., Paw, B. H., Drejer, A., Barut, B., Zapata, A., et al. (2000) · Nature · doi:10.1038/35001596 · Cited by 1,667
McKie, A. T., Marciani, P., Rolfs, A., Brennan, K., Wehr, K., Barrow, D., Miret, S., Bomford, A., Peters, T. J., Farzaneh, F., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80425-6 · Cited by 1,422
A Novel Mammalian Iron-regulated Protein Involved in Intracellular Iron Metabolism
Abboud, S., & Haile, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000713200 · Cited by 1,267
Hereditary Hemochromatosis — A New Look at an Old Disease
Pietrangelo, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra031573 · Cited by 992
Autosomal-dominant hemochrom-atosis is associated with a mutation in the ferroportin (SLC11A3) gene
Montosi, G., Donovan, A., Totaro, A., Garuti, C., Pignatti, E., Cassanelli, S., Trenor, C. C., Gasparini, P., Andrews, N. C., & Pietrangelo, A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13468 · Cited by 562
Autosomal-dominant hemochrom-atosis is associated with a mutation in the ferroportin (SLC11A3) gene
Montosi, G., Donovan, A., Totaro, A., Garuti, C., Pignatti, E., Cassanelli, S., Trenor, C. C., Gasparini, P., Andrews, N. C., & Pietrangelo, A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200113468 · Cited by 557
A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis
Njajou, O. T., Vaessen, N., Joosse, M., Berghuis, B., van Dongen, J. W. F., Breuning, M. H., Snijders, P. J. L. M., Rutten, W. P. F., Sandkuijl, L. A., Oostra, B. A., et al. (2001) · Nature Genetics · doi:10.1038/90038 · Cited by 492
Knutson, M. D., Oukka, M., Koss, L. M., Aydemir, F., & Wessling-Resnick, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409409102 · Cited by 479
Hepcidin in iron overload disorders
Papanikolaou, G., Tzilianos, M., Christakis, J. I., Bogdanos, D., Tsimirika, K., MacFarlane, J., Goldberg, Y. P., Sakellaropoulos, N., Ganz, T., & Nemeth, E. (2005) · Blood · doi:10.1182/blood-2004-12-4844 · Cited by 445
Pietrangelo, A. (2003) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2003.08.003 · Cited by 382
The discovery of the new haemochromatosis gene
Brissot, P. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00142-9 · Cited by 313
Hereditary Hemochromatosis in Adults without Pathogenic Mutations in the Hemochromatosis Gene
Pietrangelo, A., Montosi, G., Totaro, A., Garuti, C., Conte, D., Cassanelli, S., Fraquelli, M., Sardini, C., Vasta, F., & Gasparini, P. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411003 · Cited by 265
Courselaud, B., Pigeon, C., Inoue, Y., Inoue, J., Gonzalez, F. J., Leroyer, P., Gilot, D., Boudjema, K., Guguen-Guillouzo, C., Brissot, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202653200 · Cited by 245
In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations
Schimanski, L. M., Drakesmith, H., Merryweather-Clarke, A. T., Viprakasit, V., Edwards, J. P., Sweetland, E., Bastin, J. M., Cowley, D., Chinthammitr, Y., Robson, K. J. H., et al. (2005) · Blood · doi:10.1182/blood-2004-11-4502 · Cited by 212
Self-citationGordeuk, V. R., Caleffi, A., Corradini, E., Ferrara, F., Jones, R. A., Castro, O., Onyekwere, O., Kittles, R., Pignatti, E., Montosi, G., et al. (2003) · Blood Cells, Molecules, and Diseases · doi:10.1016/s1079-9796(03)00164-5 · Cited by 198
Devalia, V., Carter, K., Walker, A. P., Perkins, S. J., Worwood, M., May, A. M., & Dooley, J. S. (2002) · Blood · doi:10.1182/blood-2001-11-0132 · Cited by 190
Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis
Wallace, D. F., Pedersen, P. L., Dixon, J. L., Stephenson, P. M., Searle, J. W., Powell, L. W., & Subramaniam, V. N. (2002) · Blood · doi:10.1182/blood.v100.2.692 · Cited by 174
Sham, R. L., Phatak, P. D., West, C., Lee, P., Andrews, C., & Beutler, E. (2005) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2004.12.002 · Cited by 146
Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans
Beutler, E., Barton, J. C., Felitti, V. J., Gelbart, T., West, C., Lee, P. L., Waalen, J., & Vulpe, C. D. (2003) · Blood Cells Molecules and Diseases · doi:10.1016/s1079-9796(03)00165-7 · Cited by 129
The hemochromatosis protein HFE inhibits iron export from macrophages
Drakesmith, H., Sweetland, E., Schimanski, L., Edwards, J., Cowley, D., Ashraf, M., Bastin, J., & Townsend, A. R. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242614699 · Cited by 128
Self-citationA valine deletion of ferroportin 1: a common mutation in hemochromatosis type 4?
Roetto, A., Merryweather‐Clarke, A. T., Daraio, F., Livesey, K., Pointon, J. J., Barbabietola, G., Piga, A. G., Mackie, P. H., Robson, K., & Camaschella, C. (2002) · Blood · doi:10.1182/blood-2002-03-0693 · Cited by 103
Self-citationCazzola, M., Cremonesi, L., Papaioannou, M., Soriani, N., Kioumi, A., Charalambidou, A., Paroni, R. C., Romtsou, K., Levi, S., Ferrari, M., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03946.x · Cited by 93
A novel mutation in ferroportin1 is associated with haemochromatosis in a Solomon Islands patient
Arden, K. E., Wallace, D. F., Dixon, J. L., Summerville, L., Searle, J. W., Anderson, G. J., Ramm, G. A., Powell, L. W., & Subramaniam, V. N. (2003) · Gut · doi:10.1136/gut.52.8.1215 · Cited by 84
Wallace, D. F., Clark, R. M., Harley, H. A. J., & Subramaniam, V. N. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2003.12.008 · Cited by 83
Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload
Jouanolle, A., Douabin-Gicquel, V., Halimi, C., Loréal, O., Fergelot, P., Delacour, T., de Lajarte‐Thirouard, A., Turlin, B., Gall, J. L., Cadet, E., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00148-x · Cited by 79
Townsend, A., & Drakesmith, H. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07885-6 · Cited by 79
Self-citationGenotypic and phenotypic heterogeneity of African Americans with primary iron overload
Barton, J. C., Acton, R. T., Rivers, C. A., Bertoli, L. F., Gelbart, T., West, C., & Beutler, E. (2003) · Blood Cells Molecules and Diseases · doi:10.1016/s1079-9796(03)00166-9 · Cited by 67
Beutler, E. (2004) · Science · doi:10.1126/science.1107224 · Cited by 63
Recent advances in understanding haemochromatosis: a transition state
Robson, K., Merryweather-Clarke, A. T., Cadet, E., Viprakasit, V., Zaahl, M. G., Pointon, J. J., Weatherall, D. J., & Rochette, J. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.020644 · Cited by 62
Self-citation(2003) · PubMed · Cited by 59
Dominant Hemochromatosis Due to N144H Mutation of SLC11A3: Clinical and Biological Characteristics
Njajou, O. T., Jong, G. D., Berghuis, B., Vaessen, N., Snijders, P. J. L. M., Jp, G., Wilson, J. H. P., Breuning, M. H., Oostra, B. A., Heutink, P., et al. (2002) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2002.0581 · Cited by 48
Davies, P. S., & Enns, C. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400537200 · Cited by 47
The Hemochromatosis N144H Mutation of SLC11A3 Gene in Patients with Type 2 Diabetes
Njajou, O. T., Vaessen, N., Oostra, B. A., Heutink, P., & van Duijn, C. M. (2002) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2002.3299 · Cited by 13
Cited by
Sorted by citations
Ganz, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2013 · Cited by 1,122
“On the ferroportin side, identification of the potential receptor site was greatly aided by the discovery of an informative family which manifested resistance to hepcidin as a result of an isosteric C326S substitution in ferroportin (63, 67, 218, 219), located in an extracellular loop (FIGURE 4) in both of the reasona…”
BackgroundRegulation of Iron Metabolism by Hepcidin
Nemeth, E., & Ganz, T. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111303 · Cited by 756
Hepcidin and the iron-infection axis
Drakesmith, H., & Prentice, A. M. (2012) · Science · doi:10.1126/science.1224577 · Cited by 686
Self-citationAndrews, N. C., & Schmidt, P. J. (2006) · Annual Review of Physiology · doi:10.1146/annurev.physiol.69.031905.164337 · Cited by 671
Drakesmith, H., Nemeth, E., & Ganz, T. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.09.006 · Cited by 638
“Several ferroportin mutations associated with partial resistance to hepcidin (Drakesmith et al., 2005) affect amino acids located within the cell membrane and do not prevent hepcidin binding (Fernandes et al., 2009) but likely interfere with the conformational change that is required to initiate…”
BackgroundSelf-citation
Metadata
- Authors
- Drakesmith, H., Schimanski, L. M., Ormerod, E., Merryweather-Clarke, A. T., Viprakasit, V., Edwards, J. P., Sweetland, E., Bastin, J. M., Cowley, D., Chinthammitr, Y., Robson, K. J. H., & Townsend, A. R. M.
- Affiliations
- Siriraj Hospital (TH)
- From the Weatherall Institute of Molecular Medicine, Oxford, United Kingdom; Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford, United Kingdom; Department of Paediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; and Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2005-08-01
- Volume
- 106
- Issue
- 3
- Pages
- 1092-1097
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2131823953
- Cited by
- 264
- References
- 34
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 9 · 2019: 9 · 2018: 13 · 2017: 14 · 2016: 11 · 2015: 9 · 2014: 10 · 2013: 14 · 2012: 11
- FWCI
- 15.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- ferroportin, hepcidin, hemochromatosis, iron export, iron overload, transferrin saturation, Kupffer cells, liver iron deposition, iron homeostasis
- MeSH terms
- Ferroportin, Cell Line, Drug Resistance, Gene Expression Regulation, Hemochromatosis, Humans, Iron, Iron Radioisotopes, Transferrin, Mutation, Missense, Antimicrobial Cationic Peptides, Cation Transport Proteins, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
